Legend Biotech Corporation (FRA:9LB)

Germany · Delayed Price · Currency is EUR

16.80

-2.80 (-14.29%)

Last updated: Jul 28, 2026, 8:10 AM CET

Legend Biotech Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,139	1,029	627.3	285.1	117.01	68.83
Revenue Growth	56.38%	64.02%	120.03%	143.66%	70.00%	-8.23%
Gross Profit	626.09	620.8	392.7	140.9	51.64	68.83
Operating Income	-131.63	-136.5	-309.5	-528.1	-434.93	-406.3
Net Income	-250.27	-296.8	-177	-518.3	-446.35	-403.58
Earnings Per Share	-1.36	-1.62	-0.96	-2.94	-2.80	-2.86
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
License	81.12	83.8	138.4	35.16	50	65.4
Collaboration	1,058	944.8	482.58	249.8	66.68	-
Other Service	-	0.3	6.26	0.18	0.33	3.42
Revenue (Total)	1,139	1,029	627.3	285.1	117.01	68.83

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	834.6	948.6	1,123	1,309	1,026	882.4
Total Debt	123.3	94.6	49.4	47.34	23.6	2.5
Net Cash (Debt)	711.3	854	1,073	1,261	1,002	879.89
Net Cash Growth	-24.99%	-20.42%	-14.92%	25.88%	13.88%	75.17%
Net Cash Per Share	3.85	4.63	5.87	7.16	6.30	6.25

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-81.54	-100.2	-144	-393.3	-201.28	-198.47
Capital Expenditures	-	-28.6	-14.1	-20.1	-20.93	-42.2
Free Cash Flow	-81.54	-128.8	-158.1	-413.4	-222.21	-240.66
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	54.98%	60.34%	62.60%	49.42%	44.14%	100.00%
Operating Margin	-11.56%	-13.27%	-49.34%	-185.23%	-371.72%	-590.32%
Pretax Margin	-20.78%	-27.47%	-25.20%	-182.46%	-380.94%	-591.63%
Profit Margin	-20.99%	-28.85%	-28.22%	-181.80%	-381.48%	-586.38%
FCF Margin	-7.16%	-12.52%	-25.20%	-145.00%	-189.91%	-349.67%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Forward PE	25.08	150.43	-	-	-	-
PS Ratio	3.32	3.91	9.53	38.39	70.43	104.45